Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05210790 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
A Phase 3 study of Polycythemia Vera, sponsored by Protagonist Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 293
- Enrollment target
- 20
- Study locations
NCT05210790 is a Phase 3 study of Polycythemia Vera that is active but no longer recruiting, run by Protagonist Therapeutics. The registered enrollment target is 293 participants, below the 327-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT05210790, a Phase 3 study of Polycythemia Vera, is active but no longer recruiting, sponsored by Protagonist Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 293 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rusfertide
Study Locations (20)
California
- City of Hope Medical Center, Duarte - Duarte
- California Cancer Associates for Research and Excellence - Fresno - Fresno
- Marin Cancer Care - Greenbrae
- City of Hope Medical Center, Lenner - Irvine
- University of California, San Diego (UCSD) - Moores Cancer Center - La Jolla
- University of California, Los Angeles (UCLA) - Medical Center - Los Angeles
- Stanford University - Palo Alto
- Pomona Valley Hospital Medical Center - Pomona
- Sharp Memorial Hospital - San Diego
- University of California, San Francisco - San Francisco
- City of Hope Medical Center, Upland - Upland
Colorado
- Rocky Mountain Cancer Centers - Aurora
- University of Colorado - Aurora Cancer Center - Aurora
- Rocky Mountain Cancer Centers - Boulder - Boulder
- Rocky Mountain Cancer Centers - Colorado Springs
- Rocky Mountain Cancer Centers - Colorado Springs
- Rocky Mountain Cancer Centers - Denver
- Rocky Mountain Cancer Centers - Lakewood
Alabama
- Infirmary Cancer Care - Mobile
Arizona
- Palo Verde Hematology-Oncology - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 293 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05210790
The ClinicalTrials.gov registry entry for NCT05210790 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 293 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 327-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (10% lower). The listed sponsor is Protagonist Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Polycythemia Vera appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05210790 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT05210790 about?
NCT05210790 is a clinical study titled "A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera". The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.
What is the current status of trial NCT05210790?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 293 participants. The study started on 2022-04-01. Estimated completion is 2027-06.
What conditions does trial NCT05210790 study?
This clinical trial studies the following conditions: Polycythemia Vera.
What interventions are being tested in trial NCT05210790?
The interventions under investigation include: Placebo (DRUG), Rusfertide (DRUG).
Who is sponsoring clinical trial NCT05210790?
This trial is sponsored by Protagonist Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05210790 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycythemia Vera
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
RECRUITING · Phase 3
-
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
RECRUITING · Phase 3
-
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
ACTIVE NOT RECRUITING · Phase 3
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Ruxolitinib in Thrombocythemia and Polycythemia Vera
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.